Literature DB >> 24681125

One Health approach to Rift Valley fever vaccine development.

Jeroen Kortekaas1.   

Abstract

Since its discovery in the 1930s, Rift Valley fever virus (RVFV) spread across the African continent and invaded the Arabian Peninsula and several islands off the coast of Southeast Africa. The virus causes recurrent outbreaks in these regions, and its continued spread is of global concern. Next-generation veterinary vaccines of improved efficacy and safety are being developed that can soon be used for the widespread vaccination of livestock. However, due to regulatory and economic challenges, vaccine manufacturers have been reluctant to develop a human vaccine. Recent innovations in veterinary vaccinology, animal models and licensing strategies can now be used to overcome these hurdles. This paper reviews the historical impact of RVFV on human health and proposes strategies to develop and license a next-generation vaccine for both animals and humans.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Human; One Health; Rift Valley fever virus; Vaccine; Veterinary

Mesh:

Substances:

Year:  2014        PMID: 24681125     DOI: 10.1016/j.antiviral.2014.03.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  25 in total

Review 1.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

Review 2.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

Review 3.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

Review 4.  Rift Valley Fever.

Authors:  Amy Hartman
Journal:  Clin Lab Med       Date:  2017-03-22       Impact factor: 1.935

5.  Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.

Authors:  Hoai J Ly; Shoko Nishiyama; Nandadeva Lokugamage; Jennifer K Smith; Lihong Zhang; David Perez; Terry L Juelich; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Vaccine       Date:  2017-10-20       Impact factor: 3.641

6.  Comparison of Rift Valley fever virus replication in North American livestock and wildlife cell lines.

Authors:  Natasha N Gaudreault; Sabarish V Indran; P K Bryant; Juergen A Richt; William C Wilson
Journal:  Front Microbiol       Date:  2015-06-30       Impact factor: 5.640

7.  MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters.

Authors:  Brian B Gowen; Jonna B Westover; Eric J Sefing; Kevin W Bailey; Shoko Nishiyama; Luci Wandersee; Dionna Scharton; Kie-Hoon Jung; Tetsuro Ikegami
Journal:  Front Microbiol       Date:  2015-06-29       Impact factor: 5.640

8.  Experimental Infection of Calves by Two Genetically-Distinct Strains of Rift Valley Fever Virus.

Authors:  William C Wilson; A Sally Davis; Natasha N Gaudreault; Bonto Faburay; Jessie D Trujillo; Vinay Shivanna; Sun Young Sunwoo; Aaron Balogh; Abaineh Endalew; Wenjun Ma; Barbara S Drolet; Mark G Ruder; Igor Morozov; D Scott McVey; Juergen A Richt
Journal:  Viruses       Date:  2016-05-23       Impact factor: 5.048

9.  Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever.

Authors:  George M Warimwe; Joseph Gesharisha; B Veronica Carr; Simeon Otieno; Kennedy Otingah; Danny Wright; Bryan Charleston; Edward Okoth; Lopez-Gil Elena; Gema Lorenzo; El-Behiry Ayman; Naif K Alharbi; Musaad A Al-dubaib; Alejandro Brun; Sarah C Gilbert; Vishvanath Nene; Adrian V S Hill
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

10.  Advancing vector biology research: a community survey for future directions, research applications and infrastructure requirements.

Authors:  Alain Kohl; Emilie Pondeville; Esther Schnettler; Andrea Crisanti; Clelia Supparo; George K Christophides; Paul J Kersey; Gareth L Maslen; Willem Takken; Constantianus J M Koenraadt; Clelia F Oliva; Núria Busquets; F Xavier Abad; Anna-Bella Failloux; Elena A Levashina; Anthony J Wilson; Eva Veronesi; Maëlle Pichard; Sarah Arnaud Marsh; Frédéric Simard; Kenneth D Vernick
Journal:  Pathog Glob Health       Date:  2016-08-11       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.